March 13, 2026 10:20 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Nobody will hire them': Supreme Court says menstrual leave would backfire, hurt women's careers | Rupee sinks to record low as West Asia conflict shakes Indian markets | ₹20 lakh crore wiped out: Indian markets post worst week in 4 years amid West Asia tensions | America’s flip-flop on Russian oil: How Washington sends conflicting signals to India | Big diplomatic win! Iran allows Indian oil tankers through the Strait of Hormuz | ‘It was over in the first hour’: Trump declares victory in Iran war, says ‘nothing left to target’ | Indian-origin shopkeepers face targeted attacks in Wembley; Somali men suspected | Iran pulls out of 2026 FIFA World Cup amid war with US-Israel | Supreme Court allows first-ever passive euthanasia for 32-year-old man in coma for 13 years | As Iran-US war disrupts global gas supply, India issues guidelines to manage shortages
Bharat Biotech-Covaxin
Image tweeted by @IndianEmbassyTR

Covaxin supplied to 18 states directly since May 1: Bharat Biotech

| @indiablooms | May 12, 2021, at 05:24 am

New Delhi/IBNS: Vaccine maker Bharat Biotech on Tuesday informed that it has directly supplied Covaxin to 18 states since May 1.

The pharmaceutical brand also urged people to get vaccinated assuring that it will continue a steady supply of vaccines to the states.

"COVAXIN® has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine. Get yourself and your loved ones vaccinated," the company said in a statement.

The company is supplying its vaccine directly to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu and Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh, and West Bengal.

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research (ICMR).

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

On April 29, Bharat Biotech reduced the price of Covaxin from Rs 600 per dose to Rs 400 for the state governments in view of the challenges faced by the already overstretched health system, the company had said.

The vaccination programme in India which started on Jan 16, was last month widely expanded to include citizens above 18 years of age as a part of the Centre's Liberalised Pricing & Accelerated National COVID-19 Vaccination strategy.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.